VANCOUVER, British Columbia, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) ("the Company"), a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response (DDR) technologies, today announced a summary of the Company’s presentation at the sixth biennial Canadian Cancer Research Conference (CCRC), being held virtually November 8-11, 2021.
Rakovina Therapeutics Presents at the 6th biennial Canadian Cancer Research Conference
Provided Content: Content provided by Globe Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.
